Kyongbo Pharmaceutical경보제약
214390 · KOSPI · ₩214390 · 경보제약
₩5,190▲ ₩20 (0.39%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 38.4% | 38.7% | 34.5% | 29.2% | 22.6% | 20.7% |
| Operating margin | 0.9% | 1.3% | 4.4% | 2.6% | 0.7% | −3.9% |
| Net margin | 1.7% | 0.1% | 1.9% | 1.4% | 0.3% | −4.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +5.8% | +10.7% | +10.3% | +10.2% | +15.0% | — |
| Operating income growth | −25.2% | −66.3% | +88.5% | +298.1% | +121.0% | — |
| Net income growth | +2,582.6% | −96.1% | +56.0% | +387.1% | +108.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 3.3% | 0.1% | 3.2% | 2.1% | 0.4% | −5.1% |
| Return on assets | 1.4% | 0.1% | 1.7% | 1.2% | 0.3% | −3.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 150.1% | 119.3% | 94.2% | 84.4% | 67.4% | 62.6% |
| Net debt to equity | 96.7% | 81.0% | 58.3% | 47.6% | 40.2% | 35.2% |
| Current ratio | 87.8% | 108.1% | 114.5% | 114.9% | 121.7% | 125.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kyongbo Pharmaceutical / 경보제약 / 214390 / KRX:214390
Source: KRX statistical information